A robust pipeline to treat the most resistant cancers and neurological diseases
We applied a diverse arsenal of novel therapeutic approaches.
From monoclonal and bispecific antibodies, to antibody drug conjugates, discover what we have in development.
Late-Stage Clinical Asset in Partnership with BioNTech
CTLA-4
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights
Gotistobart (ONC-392)
2L IO-resistant sq NSCLC
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights:
Gotistobart (ONC-392)*
Advanced solid tumors
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights:
Gotistobart (ONC-392)
mCRPC
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights:
*In partnership with 
Fully-owned clinical assets
PD-1/VEGF
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights
AI-081
Solid tumors
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights:
SIGLEC10
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights
ONC-841
Solid tumors
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights:
ONC-841
Alzheimer’s disease
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights:
Fully-owned pre-clinical assets
CD24
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights
ONC-783
Oncology
Preclinical
IND-enabling
Phase 1
Phase 2
Phase 3
Worldwide Rights:
More early-stage R&D pipeline assets
